Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
Personalized care matters more than numbers on a PDF
Latin America held a 3% share of the market in 2025 and is expected to grow at a significant CAGR of 14% during the projection period, driven by GLP-1 medications that are driving structural health and economic shifts across Latin America by curbing surging obesity and type-2 diabetes rates, spurring vast biopharma investments, and fundamentally changing consumer habits in the fast-moving consumer goods sector
Specifically, the 12 mg arm of retatrutide has shown the highest discontinuation figures of the three compounds at their respective top doses, though investigators have suggested that part of the rate reflects participants who reached weight loss thresholds and chose to discontinue
Regardless, the clinical safety in humans is still largely unknown
Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse
US$ 24.74
US$ 27.77
US$ 22.90
